Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV.

Am J Psychiatry. 2004 Apr;161(4):692-9.

PMID:
15056516
2.

Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program.

Ahn J, McCombs JS, Jung C, Croudace TJ, McDonnell D, Ascher-Svanum H, Edgell ET, Shi L.

Value Health. 2008 Jan-Feb;11(1):48-56. doi: 10.1111/j.1524-4733.2007.00214.x.

3.
4.

Outpatient antipsychotic treatment and inpatient costs of schizophrenia.

Marcus SC, Olfson M.

Schizophr Bull. 2008 Jan;34(1):173-80. Epub 2007 Jun 19.

5.

Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.

Hansen RA, Maciejewski M, Yu-Isenberg K, Farley JF.

Psychiatr Serv. 2012 Sep 1;63(9):920-8. doi: 10.1176/appi.ps.201100328.

PMID:
22706887
6.
7.

Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency.

Gilmer TP, Ojeda VD, Barrio C, Fuentes D, Garcia P, Lanouette NM, Lee KC.

Psychiatr Serv. 2009 Feb;60(2):175-82. doi: 10.1176/appi.ps.60.2.175.

9.

Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.

Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP.

J Manag Care Pharm. 2009 Jan-Feb;15(1):32-41.

10.

Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.

Offord S, Lin J, Mirski D, Wong B.

Adv Ther. 2013 Mar;30(3):286-97. doi: 10.1007/s12325-013-0016-5. Epub 2013 Mar 8.

PMID:
23483449
11.

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T.

Med Care. 2002 Aug;40(8):630-9.

PMID:
12187177
12.

Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.

Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR.

Psychiatr Serv. 2003 May;54(5):719-23.

PMID:
12719504
13.
14.
15.

Continuity of antipsychotic medication management for Medicaid patients with schizophrenia.

Farley JF, Wang CC, Hansen RA, Voils CI, Maciejewski ML.

Psychiatr Serv. 2011 Jul;62(7):747-52. doi: 10.1176/ps.62.7.pss6207_0747.

PMID:
21724787
16.

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV.

Psychiatr Serv. 2007 Jul;58(7):1007-10.

PMID:
17602020
17.

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.

MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP.

J Manag Care Spec Pharm. 2016 Nov;22(11):1349-1361.

18.

Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.

Loosbrock DL, Zhao Z, Johnstone BM, Morris LS.

J Ment Health Policy Econ. 2003 Jun;6(2):67-75.

PMID:
14578539
19.

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

Svarstad BL, Shireman TI, Sweeney JK.

Psychiatr Serv. 2001 Jun;52(6):805-11.

PMID:
11376229
20.

Supplemental Content

Support Center